Kornimate/medical-research-clean huggingface dataset:
intervention with tranexamic acid to reduce haemorrhage during laparoscopic myomectomy

Conditions: Uterine Fibroid; Myoma;Uterus; Tranexamic Acid Adverse Reaction

Summary: this research is planned as a randomised double-blind controlled trial. interventions to reduce haemorrhage during laparoscopic myomectomy for fiboids is important. i̇ntraoperative tranexamic acid usage can reduce haemorrhage and related symptoms when given during laparoscopic myomectomy. there is no randomised controlled trials in literature about tranexamic acid usage in laparoscopic gynecological operations.

researchers planned this trial by firstly randomising the patients. 1 gr tranexamic acid in 100 ml salin will bi given by initial of the anesthesia of the patient, the other group will be taken only 100ml saline solution. randomising will be double blind and only anesthesiologist will see if the paient is in working group or control group. than researchers provide laparoscopic myomectomy with same prothocol to each patient. at the end of the operation, researchers will record all the parameters during operation like; operation starting and ending time, the amount of bleeding, time of suturing, the size, location and count of myoma uteri, complications, weight of myoma uteri and the change of haemoglobine levels before and after operation.

Eligibility criteria:
inclusion criteria: * myoma uteri * appropiate for laparoscopy exclusion criteria: * malignancy

Keywords: uterin fibroid, laparoscopic myomectomy
study to evaluate the safety of 3 new 6:2 influenza virus reassortants in adults

Conditions: Influenza; Healthy

Summary: this prospective annual release study is designed to evaluate the safety on new influenza virus vaccine strains to be included in flumist quadrivalent for the 2013-2014 influenza season.

this prospective, randomized, double-blind, placebo-controlled release study will enroll approximately 300 healthy adults 18 to 49 years of age. eligible subjects will be randomly assigned in a 4:1 fashion to receive a single dose of trivalent vaccine or placebo by intranasal spray. randomization will be stratified by site. this study will be conducted at 3 sites in the united states of america. each subject will receive 1 dose of investigational product on day 1. the duration of study participation for each subject is the time from study vaccination through 180 days after study vaccination.

Eligibility criteria:
inclusion criteria: * age 18 through 49 years * written informed consent * subject available by telephone * ability to understand and comply with the requirements of the protocol, as judged by the investigator exclusion criteria: * concurrent enrollment in another clinical study up to 180 days after receipt of investigational product (day 181) * history of hypersensitivity to any component of the vaccine, including egg or egg protein or serious, life threatening, or severe reactions to previous influenza vaccinations * any condition for which the inactivated influenza vaccine is indicated, including chronic disorders of the pulmonary or cardiovascular systems (example \[eg\], asthma), chronic metabolic diseases (eg, diabetes mellitus), renal dysfunction, or hemoglobinopathies that required regular medical follow-up or hospitalization during the preceding year * acute febrile (greater than \[\>\] 100.0 degrees fahrenheit \[f\] oral or equivalent) and/or clinically significant respiratory illness (example, cough or sore throat) within 14 days prior to randomization * any known immunosuppressive condition or immune deficiency disease, including human immunodeficiency virus infection, or ongoing immunosuppressive therapy * history of guillain-barré syndrome

Keywords: trivalent influenza flumist quadrivalent vaccine prevention healthy
pilot study about safety and efficacy of atomized intrapleural lidocaine during pleuroscopy

Conditions: Pain

Summary: this study will evaluate the potential to decrease the use of iv anesthesia drugs in patients undergoing pleuroscopy administering lidocane standardly applied to the skin in combination with atomized lidocaine applied into the pleural cavity.

most patient discomfort results from direct manipulation or contact with the parietal pleura during chest tube placement, talc instillation or pleural biopsy. this study intends to use combined iv, intradermal and intrapleural anesthesia during pleuroscopy procedures. intrapleural atomized lidocaine will be applied directly to the parital pleura. this study will evaluate intravenous anesthesia reduction in subjects treated with intrapleural lidocaine, reduction in total procedure timeby minimizing interruptions due to poor pain control, reduce perioperative pain scores and improve patient comfort nad to determine safety of fixed dosage of 3 mg/kg intrapleural lidocaine given during pleuroscopy.

Eligibility criteria:
inclusion criteria: * patients diagnosed with pleural disease * patients undergoing pleuroscopy with talc with or w/o biopsy * patients aged 18 - 85 * patients capable of signing informed consent exclusion criteria: * severe congestive heart failure * hepatic failure, bilirubin \> 2mg/dl, alt,ast 3xuln * prior use lidocaine in 48 hrs * hx sa drug reaction to lidocaine or amide local anesthetics * second or third degree heart block (w/o pacemaker) * sever sinoatrial block (w/o pacemaker) * concurrent treatment with quinidine, flecainide, dsopyramide, procainamide (classi antirrhythmic agents) * prior use or amiodarone hydrochloride * systolic bp \< 90mmhg * bradycardia * accelerated idioventricular rhythm

Keywords: pain control
the effect of the aldh2 gene polymorphism on the propofol potency for inducing loss of consciousness

Conditions: Propofol

Summary: the aim of this study is to determine whether aldh2 gene polymorphisms (g/g, g/a a/a) have effect on the potency of propofol.


Eligibility criteria:
inclusion criteria: * asa ii exclusion criteria: * asa iii-iv * osas * hepatic and renal insufficiency

Keywords: propofol aldh2 potency
safety of brimonidine tartrate ophthalmic solution in a population of pediatric, adult, and geriatric participants

Conditions: Hyperemia

Summary: to compare the safety and tolerability of brimonidine tartrate ophthalmic solution 0.025% versus its vehicle in a population of pediatric, adult, and geriatric participants. at least 51% of participants will be 40 years of age or older.


Eligibility criteria:
inclusion criteria: * participants must be at least 5 years of age at baseline (visit 1) of either sex and any race or ethnicity; * have ocular health within normal limits, including a calculated best-corrected (if necessary) visual acuity of 0.3 logarithm of the minimum angle of resolution (logmar) or better in each eye, as measured using an early treatment of diabetic retinopathy study (etdrs) chart. exclusion criteria: * have any ocular/systemic health problems * use of any disallowed medications during the period indicated prior to baseline (visit 1) and for the duration of the study.

Keywords: ocular redness
thoracic epidural anesthesia versus paravertebral block for awake thoracotomy

Conditions: Thoracic Epidural Anesthesia; Paravertebral Block; Awake Thoracotomy

Summary: this study aims to compare paravertebral block and thoracic epidural in awake thoracotomy.

pain can often persist after thoracotomy, and the incidence of chronic pain is high, with studies revealing that 30% to 50% of patients still experience pain up to five years after surgery. thoracic epidural blockade (teb) blocks nerves that supply the chest with local anesthetic bilaterally, at the spinal cord level. it acts by reducing the onward transmission of painful nerve signals, but may not abolish them altogether. paravertebral blockade (pvb) involves injecting local anesthetic into the paravertebral space, which contains spinal nerves (and sometimes even extension of the dura), white and grey rami communicantes, the sympathetic chain, and intercostal vessels, on the side of surgery.

Eligibility criteria:
inclusion criteria: * age from 18 to 60 years. * both genders. * american society of anesthesiologists (asa) physical status classification ii or iii. * scheduled for thoracotomy. exclusion criteria: * poor cardiac function (ejection fraction less than 50%). * patients with bad pulmonary function testing (pfts). absolute contraindication to thoracic epidural anesthesia includes patient refusal, allergy to local anesthetics, coagulopathy, active neurologic disorders, skin infection at the insertion site, uncooperative patients, uncontrolled cough, and unfavorable anatomy for thoracic epidural. * thoracic spine disorders require chest wall resection or emergency thoracic surgery. * had a previous thoracotomy (scarring due to prior surgery can limit the effectiveness of paravertebral block, and these patients may have existing chronic pain).
comparison of recurrence between mini-slet and limbal-conjunctival autograft techniques in primary pterygium

Conditions: Pterygium of Right Eye; Pterygium of Left Eye; Pterygium of Both Eyes; Pterygium

Summary: the surgical treatment options for pterygium, an abnormal growth on the eye's frontal surface can be treated with several surgical techniques. the rates of pterygium coming back varies depending on the surgical technique employed and other factors related to the patient and surgery. the objective of this study is to assess the efficacy and safety of incorporating a single amniotic membrane with stem cells in the treatment of primary pterygium, aiming to enhance surgical outcomes and minimize recurrence rates.

the surgical treatment options for pterygium, an abnormal growth on the eye's surface, encompass various approaches. these include standard surgical excision, which involves removing the pterygium using traditional surgical methods and more recently simple limbal epithelial transplantation. recurrence rate of pterygium varies depending on the surgical technique employed and other factors related to the patient and surgery.the objective of this study is to assess the efficacy and safety of incorporating a single amniotic membrane with stem cells in the treatment of primary pterygium, aiming to enhance surgical outcomes and minimize recurrence rates.

Eligibility criteria:
inclusion criteria: * patients with primary nasal pterygium \> 2mm * patients who can present and continue follow-up for the duration of the study * acceptance to participate in the study by signing the informed consent. exclusion criteria: * patients with rheumatoid arthritis * collagenopathy * pregnant * infection, conjunctival inflammation or ocular trauma * glaucoma * previous ocular surgery

Keywords: pterygium, mini-slet conjunctival-limbal autograft
a study of ly3502970 in participants with normal and impaired renal function

Conditions: Renal Insufficiency; Healthy

Summary: the main purpose of this study is to assess the amount of study drug (ly3502970) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to participants with normal renal function. the safety and tolerability of ly3502970 will also be evaluated in these participants. the study will last up to 6 weeks including screening period.


Eligibility criteria:
inclusion criteria: * have a body mass index within the range 18.5 to 42.0 kilograms per meter squared (kg/m²), inclusive. * men and women who agree to use highly effective or effective methods of contraception may participate in this trial. participants with normal renal function: * healthy males or females as determined by medical history, physical examination, and other screening procedures, with normal renal function. have estimated glomerular filtration rate (egfr) of greater than or equal to 90 milliliter per minute (ml/min) participants with renal impairment: * severe renal impairment: have egfr of 15 to 29 ml/min and not requiring hemodialysis. * esrd: participants who have been on a stable hemodialysis schedule for at least 3 months prior to planned dosing. exclusion criteria: * have a current, functioning organ transplant. non-functional renal allografts may be allowed. * regularly use known drugs of abuse or show positive findings on urinary drug screen that are not otherwise explained by permitted concomitant medications. * have known allergies to ly3502970, related compounds, or any components of the formulation, or history of severe atopy. * are lactating, pregnant, or intend to become pregnant, or to breastfeed during the study. * have a history or presence of chronic or acute pancreatitis participants with renal impairment: * have hemoglobin \<8.5 g/dl. * participants with type 2 diabetes mellitus if they have taken any glucagon-like peptide-1 receptor agonists (glp1-ra) or a dipeptidyl peptidase 4 (dpp4) inhibitor in the past 6 weeks or 5 half-lives prior to dosing, whichever is longer, prior to dosing on day 1
effect of essential aminoacid supplementation and exercise on skeletal muscle function in hemodialysis patients

Conditions: Sarcopenia

Summary: sarcopenia can be easily observed in patients with hemodialysis. however, there were few studies on the precise concept and diagnostic criteria for sarcopenia in patients with hemodialysis. the investigators have already recognized the sarcopenia-associated mortality and morbidity in patients with hemodialysis. however, intervention studies on hemodialysis patients with sarcopenia have not been conducted until now. in 2021, the investigators conducted a pilot study to evaluate the effectiveness of the combined exercise and nutrition intervention for sarcopenia in patients with hemodialysis to confirm the effectiveness. this study is a follow-up study, conducted as a randomized controlled trial.

this is a prospective, 1:1 randomized controlled study with 40 patients with hemodialysis who were diagnosed as sarcopenia or frailty in our previous cohort study. combined intervention will consist of resistance exercise and nutritional supplementation for 12 weeks. the primary outcome of this study is muscle mass and handgrip strength after 12 weeks' intervention. all functional outcomes will be measured at 0, 4, 8 and 12 weeks after intervention. the data will be analysed using the intention-to-treat principle.

Eligibility criteria:
inclusion criteria: * patients with hemodialysis * community-dwellers * able to walk with or without assistive devices for more than 100 meters exclusion criteria: * a person with cancer disease. * people with psychiatric symptoms. * a person who has an absorption disorder or has a history of resection of the small intestine or colon * pregnant women * a person treated for acute bacterial infections * a person who is in a wheelchair due to inconvenience in walking.

Keywords: hemodialysis nutrition exercise
systematic review and meta-analysis of psoriasis treatments.

Conditions: Psoriasis

Summary: this project involved a systematic literature review of published trials of treatments for moderate-to-severe plaque psoriasis. data was extracted from the publications on various psoriasis endpoints including the physician global assessment (pga), dermatology life quality index (dlqi), and short-form 36 (sf-36). a traditional meta-analysis and a mixed treatment comparison was conducted on the extracted data.

this project involved a systematic literature review of published trials of treatments for moderate-to-severe plaque psoriasis. data was extracted from the publications on various psoriasis endpoints including the physician global assessment (pga), dermatology life quality index (dlqi), and short-form 36 (sf-36). a traditional meta-analysis and a mixed treatment comparison was conducted on the extracted data. we included all published randomized controlled trials of treatments for moderate-to-severe psoriasis that met the study inclusion criteria.

Eligibility criteria:
inclusion criteria: * randomized controlled clinical trials of treatments for moderate-to-severe plaque psoriasis. * trials had to evaluate at least one of the following: physician's global assessment (pga), dermatology life quality index (dlqi) and/or the short-form 36 (sf-36). exclusion criteria: observational studies * trials that did not report the physician's global assessment (pga), * dermatology life quality index (dlqi) or the short-form 36 (sf-36).

Keywords: psoriasis systematic review meta-analyses
study of gynecological follow-up concerning women with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the investigators want to evaluate gynecological follow-up concerning patients with multiple sclerosis. this study will include reproductive women (from 18 to 40 years old). patients in the study have an aftercare at the neurology department at pellegrin hospital (bordeaux).

multiple sclerosis is an inflammatory disease of central nervous system, with a prevalence rate in france of 1 case/1000 subjects (120 000 subjects in france). the average age at diagnosis is 30 years old and it affects especially women, with a sex ratio of 3 women for 1 man. many different treatments exist, depending on the severity of the pathology and the evolutivity of the disease. it is very important to understand that some treatments are not compatible with pregnancy. in these circumstances, a regular gynecological follow-up seems to be essential, to discuss contraception and pregnancy. besides, some treatments have an immunosuppressive activity that is why a gynecological aftercare is necessary, especially in the detection of papillomavirus for cervical cancer. the neurologist can advise about gynecological issues, but he cannot take care of the gynecological follow-up, that is why it is very interesting to study the quality of the gynecological follow-up. the investigators aim to study gynecological care of patients with multiple sclerosis using a questionnaire made especially for this project. the questionnaire will be filled by patients when they come in the neurology department for a consultation or during their visit at day hospital. at the same time, they will fill a standardized questionnaire about sexuality and quality of life. this project is a monocentric study realized at pellegrin hospital - bordeaux. patients with multiple sclerosis belong to a cohort of the neurology center (crcsep).

Eligibility criteria:
inclusion criteria: * aged between 18 to 40 years old ; * diagnosis of multiple sclerosis based on mcdonald criteria 2017 ; * patient whose clinical data are referenced in the european database for multiple sclerosis (edmus) clinical database (ofsep database for collecting clinical data from patients followed in the neurology department) ; * french-speaking, without comprehension disorders ; * being affiliated to health insurance ; * willing to participate and to sign informed consent. exclusion criteria: * pregnant or breastfeeding women ; * patient concerned by articles l 1121-5 to l 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent).

Keywords: multiple sclerosis gynecological care sexuality contraception
peri-operative tamsulosin and impact on voiding trial after same-day urogynecology surgery

Conditions: Postoperative Urinary Retention (POUR)

Summary: the purpose of this research study is to determine if taking tamsulosin preoperatively decreases your chances of being discharged after surgery with a foley catheter (flexible tube that drains urine from the bladder into a collection bag).


Eligibility criteria:
inclusion criteria: - patients undergoing any pelvic organ prolapse repair or incontinence surgery exclusion criteria: * any surgery involving a non-urogynecologist * patients already on an alpha blocker * baseline hypotension * history of syncope * postural orthostatic tachycardia syndrome (pots) * non-english speaker or interpreter unavailable for spanish-speaking patient * impaired cognition impeding proper consenting * any other medical contraindication for tamsulosin use * history of urinary retention requiring continuous or intermittent catheterization * patients consented for the study but then due to intraoperative complication, routine voiding trial no longer indicated due to requiring indwelling catheter or intermittent catheterization on discharge will be excluded from primary outcome analysis * pregnancy
use of ticagrelor in korean acs patients: the briliant korea registry

Conditions: Acute Coronary Syndrome

Summary: patients with acute coronary syndrome (acs) require platelet inhibition after treatment. p2y12 receptor blockage is a well-known, proved method of urgent and effective blockade of the platelet activation, and is applied to the current practice protocol. ticagrelor is a well-performing p2y12 receptor blocking agent which is used in these patients. in the same matter, it is essential to prescribe the exact dosage to optimize efficacy within the safety limits. however current studies are based on western countries, whereas there has been no ticagrelor patient registry in east-asia. thus it is reasonable to study the use of ticagrelor in a large registry of korean acs patients. the bk registry is a prospective, open-label, multi-center, real world, registry, with prospective registration of patients receiving the medication, ticagrelor. all subjects are to be followed up for 18 months after diagnosis and treatment for acs. the purpose of this study is to observe and register clinical data including major adverse cardiovascular endpoints and any total bleeding occurrence in korean acs patients treated with ticagrelor during 18 month follow-up. also, the purpose includes to determine compliance of ticagrelor during post-approval commercial use and to determine prescription pattern of ticagrelor during post-approval commercial use.


Eligibility criteria:
inclusion criteria: 1. provision of informed consent prior to any study specific procedures. alternatively, a legally authorized patient representative may agree to the patient's participation in this study and sign the informed consent form. 2. patients who are taking ticagrelor and acetylsalicylic acid daily or patients who are taking ticagrelor only according to label. all treatment modalities for acute coronary syndrome (invasive and non-invasive) are allowed. exclusion criteria: * none
a clinical trial to compare and evaluate the pharmacokinetic characteristics and the safety of fimasartan in hepatic impairment patients and healthy volunteers

Conditions: Essential Hypertension; Hepatic Impairment

Summary: to compare and evaluate the pharmacokinetic characteristics and the safety of fimasartan in hepatic impairment patients and healthy volunteers


Eligibility criteria:
inclusion criteria: \ * age: 20 - 64 years * sex: male * child-pugh score a or child-pugh score b * body weight: greater than 55 kg * written informed consent \ * age: 20 - 64 years * sex: male * body weight: greater than 55 kg * written informed consent exclusion criteria: \ * portosystemic shunt surgery * child-pugh score c * creatinine clearance \< 80ml/min * ascites \ * ast(sgot), alt(sgpt) \> 1.5 times of upper normal range * total bilirubin \> 1.5 times of upper normal range * positive drug or alcohol screening

Keywords: fimasartan hepatic impairment